Find Clinical Trial

Home » Find Clinical Trials » Phase I/II study of oral administration of S 49076 given in combination with gefitinib in patients with EGFR mutated advanced non-small-cell lung cancer who have progressed after treatment with EGFR tyrosine kinase inhibitor.

Phase I/II study of oral administration of S 49076 given in combination with gefitinib in patients with EGFR mutated advanced non-small-cell lung cancer who have progressed after treatment with EGFR tyrosine kinase inhibitor.

← Back

Study Phase	Phase 1-2

Therapeutic Area	Cancers

Indication	Solid tumors

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	S049076

Active Substance Code	S049076

Protocol Code	CL1-49076-003

EudraCT Code	2015-002646-31

Documents and links

Lay summary

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.